The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients

BMC Gastroenterology

Research Article

Rafael Estevan¹  Mariam Aguas²  Marisa Iborra²  Guillermo Bastida³  Pilar Nos³  Belén Beltrán³  Vicente Ortiz³  Julio Ponce³  Vicente Garrigues³ 

[1] Coloproctology Unit, La Fe Hospital, Valencia, Campanar Avenue 21, 46009, Valencia, Spain;Gastroenterology Unit, La Fe Hospital, Valencia, 21 Campanar Avenue, 46009, Valencia, Spain;Gastroenterology Unit, La Fe Hospital, Valencia, 21 Campanar Avenue, 46009, Valencia, Spain;Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), 170 Villarroel Street, escalera 12 planta 4, 08036, Barcelona, Spain;

关键词: Inflammatory Bowel Disease;    Ulcerative Colitis;    Infliximab;    Inflammatory Bowel Disease Patient;    Ulcerative Colitis Patient;   

DOI  :  10.1186/1471-230X-10-26

 received in 2009-04-05, accepted in 2010-03-02,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundThe effect of thiopurine immunomodulators on health-related quality of life (HRQoL) in patients with inflammatory bowel disease (IBD) has been controversial. The aims were to evaluate the HRQoL in patients with IBD treated with thiopurines and assess the short- and long-term impacts of the treatment on HRQoL.MethodsNinety-two consecutive patients who started treatment with thiopurines were prospectively included. Evaluation of HRQoL was performed at months 0, 6, and 12 using two questionnaires, the Short-Form Health Survey (SF-36) and the Inflammatory Bowel Disease Questionnaire (IBDQ).ResultsBaseline score of IBDQ was 4,6, range (2,31-6,84), with an impairment of the five dimensions of HRQoL compared with inactive patients. Results obtained in 8 dimensions of SF-36 showed worse HRQoL than Spanish general population. At 6 months patients had a significant improvement in overall IBDQ score -5,8 (1,58 -6,97)- and also in all IBDQ dimensions. All the 8 dimensions of SF-36 obtained a significant improvement. At twelve months score of IBDQ was 6,1, range (2,7-6,98), with improvement in all dimensions compared with baseline and 6 months. SF-36 showed a similar significant improvement in all subscales.ConclusionsThiopurine immunomodulators alone or with other treatments have a positive and long lasting impact on HRQoL of IBD patients.

【 授权许可】

CC BY   
© Bastida et al; licensee BioMed Central Ltd. 2010